

1 **Age-related Central Auditory Processing Disorder, MCI, and Dementia**
2 **in an Older Population of Southern Italy**

3
4 Rodolfo Sardone, AuD, MPh¹, Petronilla Battista, PhD², Rossella Donghia, Msc¹,
5 Madia Lozupone, MD, PhD^{1,3}, Rosanna Tortelli, MD, PhD⁴, Vito Guerra, Msc¹,
6 Alessandra Grasso, Msc¹, Chiara Griseta, Msc¹, Fabio Castellana, Msc¹, Roberta Zupo, Msc¹,
7 Luisa Lampignano, Bsc¹, Giancarlo Sborgia, MD⁴, Rosa Capozzo, MD⁵,
8 Ilaria Bortone, PhD⁴, Roberta Stallone, Msc¹, Maria Luisa Fiorella, MD⁶,
9 Andrea Passantino, MD, PhD², Gianluigi Giannelli, MD¹, Davide Seripa, PhD⁷,
10 Francesco Panza, MD, PhD^{1*}, Giancarlo Logroscino, MD, PhD^{3,5}, Nicola Quaranta, MD^{4,6}

11
12 1 Population Health Research Unit, National Institute of Gastroenterology and Research Hospital
13 IRCCS “S. De Bellis” Castellana Grotte, Bari, Italy

14 2 Istituti Clinici Scientifici Maugeri IRCCS, Institute of Bari, Pavia, Italy

15 3 Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari
16 Aldo Moro, Bari, Italy

17 4 Institute of Neurology, University College of London, London, UK

18 5 Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research
19 in Neurology, University of Bari Aldo Moro, Pia Fondazione Cardinale G Panico, Tricase, Italy.

20 6 Otolaryngology Unit, Section of Otologic and Neurotologic Surgery, Department of Basic
21 Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy

22 7 Research Laboratory, Complex Structure of Geriatrics, Department of Medical Sciences,
23 Fondazione IRCCS Casa Sollievo della Sofferenza, Foggia, Italy

24

25 * **Corresponding author:**

26 Francesco Panza, MD, PhD

27 Population Health Research Unit,

28 National Institute of Gastroenterology and Research Hospital IRCCS “S. De Bellis”

29 Castellana Grotte, Bari, Italy

30 National Institute of Gastroenterology and Research Hospital IRCCS “S. De Bellis”

31 Via Turi, 27, 70013 - Castellana Grotte, Bari, Italy

32 Tel. +39 0804994111;

33 email: geriat.dot@uniba.it

34

35 **The results of this paper have been presented at the AAO-HNSF Annual Meeting 2019**

36 **(oral presentation)**

37

38 **ABSTRACT**

39 **Objective:** We explored the associations of age-related central auditory processing disorder
40 (CAPD) with mild cognitive impairment (MCI) and dementia in an older population-based
41 cohort in Apulia, Southern Italy (GreatAGE Study).

42 **Study design:** Cross-sectional data from a population-based study.

43 **Setting:** Castellana Grotte, Bari, Italy.

44 **Subjects and Methods:** Between 2013 and 2018, MCI, dementia, age-related CAPD (no
45 disabling hearing loss and <50% at the Synthetic Sentence Identification Test), neurological,
46 neuropsychological examinations and serum metabolic biomarkers assays were investigated on
47 1647 healthy volunteers aged > 65 years.

48 **Results:** The prevalences of age-related CAPD, MCI, and dementia were 14.15%, 15.79%, and
49 3.58%, respectively. Among MCI and demented subjects, 19.61% and 42.37%, respectively, had
50 age-related CAPD. In the regressive models, age-related CAPD was associated with MCI (odds
51 ratio:1.50; 95% confidence interval:1.01 to 2.21) and dementia (odds ratio:2.23; 95% confidence
52 interval:1.12 to 4.42). Global cognition scores were positively associated with increasing
53 Synthetic Sentence Identification scores in linear models. All models were adjusted for
54 demographics and metabolic serum biomarkers.

55 **Conclusion:** The tight association of age-related CAPD with MCI and dementia suggests the
56 involvement of central auditory pathways in neurodegeneration, but it is not clear which is the
57 real direction of this association. However, CAPD is a possible diagnostic marker of cognitive
58 dysfunction in older patients.

59
60 **KEY WORDS:** hearing loss; cognitive impairment; dementia; MCI; CAPD; central presbycusis;
61 metabolic biomarkers; cohort study; Italy; Apulia; population study

62 INTRODUCTION

63 Sensory changes, particularly hearing and vision impairments, are key modifiable risk factors in
64 dementia prevention strategies.¹ Specifically, among the potentially modifiable dementia risk
65 factors, the UK National Institute of Health and Care Excellence and the US National Institutes
66 of Health identify peripheral age-related hearing loss (ARHL) and its consequential social
67 isolation.² Nonetheless, ARHL may also precede the cognitive symptoms of Alzheimer's disease
68 by several years.^{3,4}

69 Recently, age-related central auditory processing disorder (CAPD) has been included as a
70 specific risk factor among ARHL components.⁵ CAPD is defined as a peculiar deficit in the
71 processing of auditory signals along the central auditory nervous system, including one or more
72 areas of auditory discrimination, binaural and temporal processing, clinically featured in the
73 elderly by the inability to understand speech in a noisy environment.⁶ Formally, CAPD has been
74 defined by the World Organization of Health⁵ as a diagnostic entity that involves the entire
75 lifespan. However, age-related CAPD or central presbycusis⁷ describe a specific form linked to
76 the senescence of the central auditory pathways and cortical appendages.

77 Age-related CAPD is characterized by poor speech understanding in noisy environments,
78 or against competing speech, or any other alteration in terms of acoustic features of speech
79 perception.^{5,8} As a consequence, poorer perception of auditory speech signals leads to a greater
80 reliance on visual information drawn from the talker's face. Furthermore, age-related CAPD
81 leads to developing compensatory strategies of speech understanding that require a major
82 cognitive effort.⁹ The result of the acoustic challenge is reflected in the cognitive and linguistic
83 abilities of older adults.¹⁰ Some studies revealed that elderly people with poorer hearing
84 perception showed low performance on neuropsychological tests and have a higher risk for
85 dementia.¹¹ The precise cause of this association is still debated, but it has been suggested that a

86 long period with age-related CAPD demanding major cognitive/listening effort may modify the
87 cortical networks involved in speech understanding.¹²

88 Furthermore, epidemiological studies also suggested that age-related CAPD may be
89 fundamental in determining an increased occurrence of mild cognitive impairment (MCI) and
90 dementia.⁸ This association seems to be stronger when comparing CAPD with peripheral
91 ARHL.¹³ Recently, this CAPD-cognition link has been provocatively described as “the cognitive
92 ear”, indicating that not only the ears and auditory cortex but also other associative cortical areas
93 concur in determining hearing functions.^{5,10,14} Finally, several meta analytic reviews investigated
94 associations of ARHL with later-life cognitive disorders but only few population-based studies
95 investigated possible associations of age-related CAPD with dementia^{15,16} and MCI.^{17,18} In the
96 present study, we aimed to integrate missing data in the literature concerning the association of
97 age-related CAPD and MCI and to investigate any correlation with dementia in a population-
98 based study of older subjects conducted in Castellana Grotte, Apulia, Italy.

99

100 **METHODS**

101 *Study population and laboratory and clinical evaluations*

102 Participants have been recruited from a population-based study (GretAGE Study), described in
103 detail elsewhere.¹⁹ Participants belong to a sample of community dwelling elderly (65+)
104 residents in Castellana Grotte, Apulia region, in Southern Italy. The sampling frame was the
105 health registry office list on December 31, 2014, including 19675 subjects, of which 4,021 were
106 65 years or older. All the participants signed an informed consent document, approved by the
107 IRB of the National Institute of Gastroenterology “S. De Bellis”, where they were assessed for
108 all examinations described in this study. For the included subjects, a blood sample was also
109 collected in the morning, after an overnight fast, assessing fasting glucose, total cholesterol,
110 high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol, using
111 standard automated enzymatic colorimetric methods (AutoMate 2550, Beckman Coulter, Brea,
112 Ca, US), under strict quality control. The values of systolic blood pressure (SBP) used in the
113 analyses were the mean of the last two of three sitting SBP measurements performed. Smoking
114 covariates referred to the actual smoking status or to not having quit smoking 10 years or more
115 before the date of enrollment in the study.

116

117 *Hearing assessment*

118 All participants underwent an audiological assessment. The examination was performed by a
119 certified audiologist. We collected participants’ tympanometry and stapedial reflexes (Clarinet
120 Plus, Middle Ear Analyzer, Inventis, Italy) to exclude middle and external ear disorders that
121 could induce a conductive hearing loss. Age-related hearing loss was defined as a pure tone
122 average (PTA) threshold greater than 40 dB hearing level (HL) in the better ear according to the
123 WHO definition of a disabling hearing loss,²⁰ assessed with pure tone audiometry, following
124 THE Hughson-Westlake method, in a soundproof booth with HDR 39 headphones (Sennheiser

125 electronic GmbH & Co. KG, Wedemark, Germany) and PIANO Audiometer (Inventis SRL,
126 Padova, Italy), calibrated and executed according to international standards for audiometric
127 testing. The PTA was calculated at the frequencies of 0.5, 1, 2 and 4 KHz. Only the participants
128 with a PTA \leq 40 dB HL in the better ear^{5,21} underwent the Italian version of the Synthetic
129 Sentence Identification with Ipsilateral Competitive Message (SSI-ICM) test,²² a sensitive and
130 specific measure to define speech intelligibility central patterns. The test consists of
131 administering, for each ear, a primary signal of ten synthetic sentences while a contextual
132 competition signal is going on (a male talker reading a passage). **The primary signal must be sent**
133 **at a comfortable hearing level for the normal hearing listener (+50dB SPL over the PTA).** The
134 rate of identification of sentences is expressed in proportion (0-100%) to various
135 primary/competitive ratios (0, +5, +10 dB SPL)²². According to Gates and other authors,^{5,23,24}
136 age-related CAPD was considered as present when the patient scored $<$ 50% in the better ear with
137 a 0-dB message/competition ratio (MCR). Only subjects able to perform a neuropsychological
138 assessment, so with sufficiently preserved language comprehension abilities, performed this task.
139 Finally, in order to obtain dose-response analysis also for age-related CAPD, we stratified the
140 SSI-ICM values in four quartiles by performance strata. In the present study, SSI-ICM was used
141 to assess CAPD, instead of other tests, for two major reasons: firstly, is one of the most sensitive
142 and widely used diagnostic tests to define age-related CAPD.²³ Secondly, the SSI with ipsilateral
143 competitive message appears to be more sensitive to detect dementia than the contralateral test
144 form (SSI-CCM) and other central auditory disfunctions tests.^{5,23,24}

145

146 *Neurological and neuropsychological examinations*

147 All subjects underwent a standard neurological examination, conducted by a certified
148 neurologist, exploring awareness, deambulation, cranial nerves, motor function (muscle tone,
149 straightness, and tropism), presence of pathological movements, sensory function, cerebellar and

150 sphincter functions, deep tendon reflexes and signs of diffuse cerebral suffering. Clinical
151 Dementia Rating Scale was administered to evaluate the staging of cognitive decline.²⁵ The
152 diagnosis of dementia and of MCI was made according to the Diagnostic and Statistical Manual
153 of Mental Disorders - Fifth Edition (DSM-5) criteria.²⁶

154 All participants underwent a battery of standardized neuropsychological tests, assessing
155 global cognition by the Mini Mental State Examination (MMSE)²⁷ global executive functions by
156 the Frontal Assessment Battery,²⁸ and auditory verbal memory and verbal learning by the Rey
157 Auditory Verbal Learning Test,²⁹ flexibility of thinking, attention, and planning on visual-motor
158 tasks by the Trail Making Test AB,³⁰ visuospatial skills, executive functions, and abstract
159 thinking by the Clock Drawing Test,³¹ executive functions by the Verbal Fluency Test²⁹ and
160 language production using the Boston Naming Test.³²

161

162 ***Statistical analysis***

163 Qualitative and quantitative variables are reported as frequencies and percentages and mean and
164 standard deviation, respectively. Pearson's correlation coefficients were used to assess linear
165 correlations between quantitative variables. Comparisons between three subgroups of cognitive
166 functioning (normal cognition, MCI, and dementia) were conducted using Pearson's chi-squared
167 for categorical variables and Kruskal-Wallis one-way ANOVA followed by Nemenyi post-hoc
168 test for quantitative parameters. Multiple linear regression models were used to assess the
169 association between neuropsychological raw scores and audiometric variables, adjusting for
170 confounders. Multinomial logistic regression models were run to assess associations between
171 different levels of cognitive functioning and audiometric variables, also adjusting for
172 confounders. The Polytomous Discrimination Index was used to assess the discrimination of
173 multinomial regression models. For each exposure, three models were run: an unadjusted model,
174 a partially adjusted model (for age, sex and education) and a fully adjusted model (adding blood

175 glucose level, LDL cholesterol, HDL cholesterol, SBP, and smoking status). In the linear model
176 SSI-ICM, we used the pure tone average in the better ear as interactor, in order to eliminate the
177 effect of peripheral hearing loss even in mild and moderate deficits (<40 dB HL). Linear trend in
178 the cognitive variables at the linear predictor level was assessed using a Likelihood Ratio Test
179 for trend in the fully adjusted model. The threshold for statistical significance was set at $p < 0.05$.
180 All statistical analyses were conducted using R (v 3.3.1) and Stata 14 (StataCorp. 2017. Stata
181 Statistical Software: Release 15. College Station, TX: StataCorp LLC).

182

183 **RESULTS**

184 *Descriptive analysis*

185 The initial study sample included 1647 participants. The overall prevalence of age-related CAPD
186 was 14.15% (n=233), being more prevalent in males (55.36%) than females (42.92%). The
187 mean age of the sample was 74.23 ± 6.40 years, with a mean education level of 7.27 ± 3.85 years,
188 and an MMSE mean score of 26.83 ± 3.76 . The prevalence of age-related CAPD increased with
189 age (Figure 1, Panel A). In our sample, we assessed 260 (15.79%) subjects with MCI, and 59
190 (3.58%) with dementia. Subjects with MCI slightly increased at age stratification, with a higher
191 distribution in males (Figure 1, Panel B). A dementia diagnosis was significantly more prevalent
192 in the older age groups, although the oldest groups had the lowest prevalence, probably due to a
193 survival effect (Figure 1, Panel C).

194 Clinical and socio-demographic characteristics of the study sample subdivided into two
195 subgroups of different cognitive impairment are shown in Table 1. Lower SSI-ICM scores (%)
196 were found in the better ear of MCI (65.02 ± 32.63) and dementia subjects (38.64 ± 32.32)
197 compared to normal (74.97 ± 29) individuals. Patients with dementia had a markedly lower SSI-
198 ICM score percentage than MCI subjects. No other statistically significant difference between
199 MCI, dementia and normal subjects were observed among the three groups, except for the
200 smoking status prevalence, that seemed to be higher in dementia and MCI subjects. Table 2
201 clearly shows that the prevalence of age-related CAPD increased significantly across categories
202 of cognitive impairment compared to the normal cognition group: 19.61% (51) in MCI and
203 42.37% (25) in dementia. Prevalences of age-related CAPD and cognitive status by age classes
204 are shown in Table 3.

205

206

207

208 ***Cognitive Impairment Diagnosis Logistic Prediction Models***

209 Table 4 show the results of multinomial logistic regression models of cognitive function
210 subgroups. We created two models: a no-covariate model (unadjusted) and a fully-adjusted
211 model (age, sex, education, total cholesterol, systolic blood pressure, glucose, smoking). In all
212 models, particularly in the fully adjusted model, age-related CAPD was a good predictor of a
213 diagnosis of MCI [odds ratio (OR): 1.50; 95% confidence interval (CI): 1.01 to 2.21] and
214 dementia (OR: 2.23; 95% CI: 1.12 to 4.42).

215

216 ***Global cognition score linear prediction models***

217 Tables 5 and 4 show the results of multiple linear regression models. The MMSE score has been
218 considered a dependent variable while the SSI-ICM score percentage, used to assess age-related
219 CAPD, has been considered as predictor. We ran two linear prediction models: an unadjusted
220 (without covariates) and a fully adjusted model (age, sex, education, total cholesterol, systolic
221 blood pressure, glucose, smoking). In the fully adjusted model, for each unit increase of the SSI-
222 ICM percentage, subjects had on average an increase of 0.02 (95% CI: 0.01 to 0.03) at the
223 MMSE score. Furthermore, to explore the possible effect of the peripheral ARHL, measured
224 with audiometric PTA, on the association between SSI-ICM and MMSE, we ran an interaction
225 model as shown in Table 5. The association remained strong and significant in the model, but the
226 interactor (SSI-ICM*PTA) did not modify the effect (p-value = 0.71).

227

228 **DISCUSSION**

229 The main important finding in the present study was that age-related CAPD was strongly
230 associated with a diagnosis of both MCI and dementia. These results suggested, at first sight, an
231 evident relationship among these conditions, previously defined as a single age-related
232 pathophysiological entity,⁵ so providing further evidence of the importance of the cognitive ear.⁵
233 The role of age-related CAPD as an accurate predictor of cognitive impairment in MCI
234 (OR:1.50; 95% CI:1.01-2.21) and dementia (OR: 2.23; 95% CI: 1.12-4.42) was definitely
235 highlighted by the logistic models.

236 To date, to the best of our knowledge, only two other population-based studies have
237 investigated and shown the association of age-related CAPD with dementia.^{23,33} Specifically, in
238 the Adult Changes in Thought (ACT) study cohort,²³ the authors found similar results in terms of
239 the prevalence of age-related CAPD in the elderly (16%), but they evaluated the dichotic process
240 using a different test (dichotic sentence identification, DSI). Concerning age-related CAPD and
241 incident dementia, they did not find a significant association using SSI-ICM, whereas they did
242 find a significant association using DSI (hazard ratio: 9.9; 95% CI: 3.6-26.7).²³ In the
243 Framingham cohort,³³ the prevalence of age-related CAPD was 16.7% and the association with
244 incident dementia was estimated as a hazard ratio of 6.07 (95% CI: 1.39-26.5). Notably, their
245 findings were obtained using the same hearing assessment employed in the present
246 study. Concerning the association between age-related CAPD and MCI, although some studies
247 reported data in longitudinal cohorts,^{18,34,35} to the best of our knowledge, there are no reports of
248 evidence collected in population-based studies. Thus, the results of the present study are the first
249 obtained in this epidemiological setting and cannot be compared with other clinical settings.

250 This finding is extremely important for the clinical practice of dementia, since they
251 indicate that hearing loss should be comprehensively assessed as it could lead to communication

252 problems with a different etiology with respect to other progressive speech/language disorders
253 due to frontotemporal dementia.³⁶

254 Furthermore, in order to define the internal validity of the inferences, we tested the dose-
255 response effect in the association between the unit increase of SSI-ICM and MMSE raw score
256 performances (β : 0.02; 95% CI: 0.01-0.03). This result is useful not only in terms of numeric
257 models, but particularly to support the inference about the role of age-related CAPD as a marker
258 of neurodegeneration and cognitive dysfunction, even in the early stages of cognitive decline.
259 One of the most debated issues in the association between age-related CAPD and cognitive
260 impairment concerns the difficulty in disentangling the effect of central hearing impairment on
261 cognition in subjects with peripheral ARHL. In fact, age-related CAPD does not determine an
262 evident perceived disability, as it occurs in subjects with a non-disabling hearing threshold and
263 emerges only in conditions of background noise. This is the reason why our findings support the
264 hypothesis that age-related CAPD is implicated in the same neurodegeneration pathways as
265 cognitive impairment. Interestingly, a seminal neuropathological study showed that amyloid- β
266 ($A\beta$) deposition was predominantly localized in central auditory pathways and absent in the
267 peripheral auditory system.³⁷ In the future, we need to obtain direct evidence of
268 neurodegeneration by collecting disease biomarkers in the area involved in auditory processing,
269 e.g., tau protein and $A\beta$. Another way to define this effect could be to employ neuroimaging
270 methods, such as functional and structural magnetic resonance imaging to study *in vivo* changes
271 of the networks involved in the degeneration. Future studies could be conducted in these
272 directions.

273 Some limitations of the present study should be acknowledged. Firstly, because of the
274 cross-sectional design, we cannot make any inference on the direction of the association because
275 of reverse causality but can estimate association only in terms of prevalence and we are not able
276 to define when the onset of the central hearing impairment occurred. However, this study is

277 currently the only population-based study exploring age-related CAPD in relation to cognition,
278 many years later than the Framingham Heart Study.³³ Another limitation was the measure used
279 to assess age-related CAPD. Indeed, SSI-ICM can only be administered in subjects with a non-
280 disabling peripheral hearing loss (>40 dB HL). We could not measure the effect of age-related
281 CAPD in individuals with peripheral ARHL, nor the synergic effect of peripheral and central
282 hearing deficits. Moreover, the SSI-ICM assess only the dichotic processing impairment and,
283 despite is one of the most used tests in population-based studies, it can define only a part of the
284 CAPD spectrum. Another important limitation was the absence of unilateral hearing loss as an
285 independent exposure category for cognitive impairment. We choose to focus, in a pragmatical
286 way, to the global effect of the disabling hearing loss on cognition. This generalization allowed
287 us to define the hearing deficit as a global impairment of the auditory functions independently of
288 the deficit of the individual ears. Nevertheless, the effect of unilateral hearing deficit (central and
289 peripheral) on cognitive impairment is a very interesting and unexplored topic and could be
290 addressed in future studies on the early stages of cognitive decline.

291

292 **CONCLUSIONS**

293 The findings of the present cross-sectional population-based study showed an association
294 between age-related CAPD and related audiological quantitative measurements in patients with
295 MCI and dementia. In clinical practice, this assumption suggests that older patients with
296 cognitive impairment and hearing difficulties, when in a noisy environment or against
297 competitive speech, should be tested for age-related CAPD and that central auditory testing may
298 well need to become a critical part of the comprehensive geriatric assessment (CGA).³⁸
299 Moreover, these findings added some knowledge to the central role of sensory interface in the
300 early detection of dementia. In fact, also olfactory biomarkers have shown to be very accurate

301 predictors of cognitive impairment.³⁹ The combined assessment of all special senses could be the
302 key for identifying some sensory dysfunctions behind the development of dementia.
303

304 **Funding Support**

305 Project realized with the financial support of the Apulia Region - Regione Puglia: DGR
306 751/2014. All instruments and clinical and administrative personnel involved in this study were
307 funded by the National Institute of Gastroenterology “IRCCS S. De Bellis” with Italian Ministry
308 of Health Direct Research Funding. This manuscript is the result of the research work and
309 funding on frailty undertaken by the “Italia Longeva: Research Network on Aging” team,
310 supported by the resources of the Italian Ministry of Health “Research Networks of National
311 Health Institutes”.

312

313 **Financial Disclosure Statement:** none.

314

315 **Acknowledgements**

316 We thank Francesco Coppola, MD, Antonio Leo, MD, Paola Mogavero, MD, Eugenio Distaso,
317 MD, Maria Rosaria Barulli, PsyD, Marianna Tursi, PsyD, Cristina Di Dio, PsyD, for their help in
318 recruiting subjects. We wish to thank Marco Piccininni, Msc, for his helpful comments, Nicola
319 Giannotti, Bsc, Stella Gioia, Bsc, Valeria La Ruccia, Bsc, for their help in scoring data, and
320 Tiziana Lozupone, Msc, for assistance in data management.

321

322 **REFERENCES**

- 323 1. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor
324 dysfunctions and Alzheimer's disease. *Alzheimers Dement.* 2015;11(1):70-98. doi:
325 10.1016/j.jalz.2014.04.514
- 326 2. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and
327 care. *Lancet.* 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6
- 328 3. Shen Y, Ye B, Chen P, et al. Cognitive Decline, Dementia, Alzheimer's Disease and
329 Presbycusis: Examination of the Possible Molecular Mechanism. *Front Neurosci.* 2018; 12:394.
330 doi:10.3389/fnins.2018.00394
- 331 4. Chern A, Golub JS. Age-related Hearing Loss and Dementia. *Alzheimer Dis. Assoc.*
332 *Disord.* 2019;33(3):285-290. doi:10.1097/wad.0000000000000325
- 333 5. Sardone R, Battista P, Panza F, et al. The Age-Related Central Auditory Processing
334 Disorder: Silent Impairment of the Cognitive Ear. *Front Neurosci.* 2019; 13:619.
335 doi:10.3389/fnins.2019.00619
- 336 6. Bellis TJ, Bellis JD. Central auditory processing disorders in children and adults. *Handb*
337 *Clin Neurol.* 2015; 129:537-556. doi:10.1016/B978-0-444-62630-1.00030-5
- 338 7. Gates GA. Central presbycusis: an emerging view. *Otolaryngol Head Neck Surg.*
339 2012;147(1):1-2. doi:10.1177/0194599812446282
- 340 8. Panza F, Lozupone M, Sardone R, et al. Sensorial frailty: age-related hearing loss and the
341 risk of cognitive impairment and dementia in later life. *Ther Adv Chronic Dis.*
342 2018;2147483647.
- 343 9. Rönnerberg J, Lunner T, Zekveld A, et al. The Ease of Language Understanding (ELU)
344 model: theoretical, empirical, and clinical advances. *Front Syst Neurosci.* 2013; 7:31.
345 doi:10.3389/fnsys.2013.00031

- 346 10. Peelle JE, Wingfield A. The Neural Consequences of Age-Related Hearing Loss. *Trends*
347 *Neurosci.* 2016;39(7):486-497. doi: 10.1016/j.tins.2016.05.001
- 348 11. Lin FR, Thorpe R, Gordon-Salant S, Ferrucci L. Hearing loss prevalence and risk factors
349 among older adults in the United States. *J Gerontol A Biol Sci Med Sci.* 2011;66(5):582-590. doi:
350 10.1093/gerona/qlr002
- 351 12. Peelle JE. Listening Effort: How the Cognitive Consequences of Acoustic Challenge Are
352 Reflected in Brain and Behavior. *Ear Hear.* 2018;39(2):204-214.
353 doi:10.1097/AUD.0000000000000494
- 354 13. Yuan J, Sun Y, Sang S, Pham JH, Kong W-J. The risk of cognitive impairment associated
355 with hearing function in older adults: a pooled analysis of data from eleven studies. *Sci Rep.*
356 2018;8(1):2137. doi:10.1038/s41598-018-20496-w
- 357 14. Panza F, Quaranta N, Logroscino G. Sensory Changes and the Hearing Loss–Cognition
358 Link: The Cognitive Ear. *JAMA Otolaryngol Head Neck Surg.* 2018;144(2):127-128. doi:
359 10.1001/jamaoto.2017.2514
- 360 15. Quaranta N, Coppola F, Casulli M, et al. The prevalence of peripheral and central hearing
361 impairment and its relation to cognition in older adults. *Audiol Neurootol.* 2014;19 Suppl 1:10-
362 14. doi:10.1159/000371597
- 363 16. Loughrey DG, Kelly ME, Kelley GA, Brennan S, Lawlor BA. Association of Age-
364 Related Hearing Loss with Cognitive Function, Cognitive Impairment, and Dementia.
365 *JAMA Otolaryngol. Head Neck Surg.* 2018;144(2):115. doi:10.1001/jamaoto.2017.2513
- 366 17. Idrizbegovic E, Hederstierna C, Dahlquist M, Kämpfe Nordström C, Jelic V, Rosenhall
367 U. Central auditory function in early Alzheimer’s disease and in mild cognitive impairment. *Age*
368 *Ageing.* 2011;40(2):249-254. doi:10.1093/ageing/afq168

- 369 18. Idrizbegovic E, Hederstierna C, Dahlquist M, Rosenhall U. Short-Term Longitudinal
370 Study of Central Auditory Function in Alzheimer's Disease and Mild Cognitive Impairment.
371 *Dement Geriatr Cogn Disord Extra*. 2013;3(1):468-471. doi:10.1159/000355371
- 372 19. Lozupone M, Panza F, Piccininni M, et al. Social Dysfunction in Older Age and
373 Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. *J Alzheimers Dis*.
374 2018;65(3):989-1000. doi:10.3233/JAD-180466
- 375 20. Duthey B. Background paper 6.21 hearing loss. Geneva: WHO Int. 2013.
376 https://www.who.int/medicines/areas/priority_medicines/BP6_21Hearing.pdf (Last accessed:
377 February 20, 2020).
- 378 21. Jerger J, Oliver TA, Pirozzolo F. Impact of central auditory processing disorder and
379 cognitive deficit on the self-assessment of hearing handicap in the elderly. *J Am Acad Audiol*.
380 1990;1(2):75-80. <https://www.ncbi.nlm.nih.gov/pubmed/2132589>.
- 381 22. Antonelli A. Sensitized speech tests: Results in brain stem lesions and diffusive CNS
382 diseases. In: *Speech Audiometry. Odense, Denmark, Second Danavox Symposium*; 1970:130-
383 139.
- 384 23. Gates GA, Anderson ML, McCurry SM, Patrick Feeney M, Larson EB. Central Auditory
385 Dysfunction as a Harbinger of Alzheimer Dementia. *Arch Otolaryngol Head Neck Surg*.
386 2011;137(4):390. doi:10.1001/archoto.2011.28
- 387 24. Gates GA, Beiser A, Rees TS, D'Agostino RB, Wolf PA. Central auditory dysfunction
388 may precede the onset of clinical dementia in people with probable Alzheimer's disease. *J Am*
389 *Geriatr Soc*. 2002;50(3):482-488. doi:10.1046/j.1532-5415.2002.50114.x
- 390 25. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the
391 staging of dementia. *Br J Psychiatry*. 1982; 140:566-572. doi:10.1192/bjp.140.6.566

- 392 26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders
393 (DSM-5®). *American Psychiatric Pub*; 2013. [https://play.google.com/store/books/details?id=-](https://play.google.com/store/books/details?id=-JivBAAAQBAJ)
394 [JivBAAAQBAJ](https://play.google.com/store/books/details?id=-JivBAAAQBAJ).
- 395 27. Measso G, Cavarzeran F, Zappalà G, et al. The mini-mental state examination:
396 Normative study of an Italian random sample. *Dev Neuropsychol*. 1993;9(2):77-85. doi:
397 10.1080/87565649109540545
- 398 28. Appollonio I, Leone M, Isella V, et al. The Frontal Assessment Battery (FAB): normative
399 values in an Italian population sample. *Neurol Sci*. 2005;26(2):108-116. doi: 10.1007/s10072-
400 005-0443-4
- 401 29. Carlesimo GA, Caltagirone C, Gainotti G, et al. The Mental Deterioration Battery:
402 Normative Data, Diagnostic Reliability and Qualitative Analyses of Cognitive Impairment. *Eur*
403 *Neurol*. 1996;36(6):378-384. doi:10.1159/000117297
- 404 30. Giovagnoli AR, Casazza M, Broggi G, Avanzin G. Verbal learning and forgetting in
405 patients with temporal lobe epilepsy. *Eur J Neurol*. 1996;3(4):345-353. doi: 10.1111/j.1468-
406 1331.1996.tb00228.x
- 407 31. Caffarra P, Gardini S, Zonato F, et al. Italian norms for the Freedman version of the
408 Clock Drawing Test. *J Clin Exp Neuropsychol*. 2011;33(9):982-988.
409 doi:10.1080/13803395.2011.589373
- 410 32. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia, PA: Lea &
411 Febiger; 1983. PsycTESTS Dataset. 2016, <https://doi.org/10.1037/t27208-000> (Last accessed:
412 January 8, 2020).
- 413 33. Gates GA, Cobb JL, Linn RT, Rees T, Wolf PA, D'Agostino RB. Central auditory
414 dysfunction, cognitive dysfunction, and dementia in older people. *Arch Otolaryngol Head Neck*
415 *Surg*. 1996;122(2):161-167. doi:10.1001/archotol.1996.01890140047010

- 416 34. Häggström J, Rosenhall U, Hederstierna C, Östberg P, Idrizbegovic E. A Longitudinal
417 Study of Peripheral and Central Auditory Function in Alzheimer's Disease and in Mild
418 Cognitive Impairment. *Dement Geriatr Cogn Dis Extra*. 2018;8(3):393-401.
419 doi:10.1159/000493340
- 420 35. Edwards JD, Lister JJ, Elias MN, et al. Auditory Processing of Older Adults With
421 Probable Mild Cognitive Impairment. *J Speech Lang Hear Res*. 2017;60(5):1427-1435.
422 doi:10.1044/2016_JSLHR-H-16-0066
- 423 36. Battista, P., Miozzo, A., Piccininni, M., Catricala, E., Capozzo, R., Tortelli, R., ... &
424 Logroschino, G. (2017). Primary progressive aphasia: a review of neuropsychological tests for the
425 assessment of speech and language disorders. *Aphasiology*, 31(12), 1359-1378.
- 426 37. Sinha UK, Hollen KM, Rodriguez R, Miller CA. Auditory system degeneration in
427 Alzheimer's disease. *Neurology*. 1993;43(4):779-785. doi:10.1212/wnl.43.4.779
- 428 38. Pilotto A, Cella A, Pilotto A, et al. Three decades of Comprehensive Geriatric
429 Assessment: Evidence coming from different healthcare settings and specific clinical conditions.
430 *J Am Med Dir Assoc*. 2017;18(2): 192.e1-192.e11. doi: 10.1016/j.jamda.2016.11.004
- 431 39. Adams DR, Kern DW, Wroblewski KE, McClintock MK, Dale W, Pinto JM. Olfactory
432 dysfunction predicts subsequent dementia in older U.S. adults. *J Am Geriatr Soc*.
433 2018;66(1):140-144. doi: 10.1111/jgs.15048

434 **Table 1.** Clinical and socio-demographic characteristics of the study sample subdivided in three
 435 subgroups of cognitive functioning: normal cognition, mild cognitive impairment (MCI) and
 436 dementia ($n=1647$).

Variables *	Cognitive functioning		
	Normal ($n=1055$)	MCI ($n=260$)	Dementia ($n=59$)
Socio-demographic			
Gender (F)	520 (49.29)	112 (43.08)	35 (59.32) ^
Age (yrs)	73.15±5.74	74.03±5.62	79.17±5.31^
Education (yrs)	7.72±3.83	6.39±3.34	3.07±3.01^
Smoker Status	498 (30.23)	664 (40.31) ^	485 (29.44) ^
Hearing Status			
Age-related CAPD (Yes)	118 (11.18)	51 (19.61) ^	25 (42.37) ^
PTA (dB HL)	24.49±5.35	26.28±5.67	26.36±5.54
SSI-ICM	74.97±29.00	65.02±32.63^	38.64±32.32^
Cognitive scores			
MMSE	27.40±2.86	27.29±1.97	14.76±3.86^
Metabolic Biomarkers			
Blood glucose (mmol/L)	105.55±26.47	103.85±23.01	111.36±40.05
Total cholesterol (mg/dL)	184.52±37.30	183.20±37.56	176.66±37.23
HDL cholesterol (mg/dL)	48.59±14.45	49.27±14.39	48.60±13.39
LDL cholesterol (mg/dL)	114.66±32.18	113.51±32.12	107.58±29.47^
SBP (mmHg)	132.75±14.55	133.49±13.92	133.40±14.23

437 *All values: mean±standard deviation (Mean±SD) for continuous variable Frequencies and
 438 percentage (%) for the categorical
 439 Abbreviations: CAPD, central auditory processing disorder; PTA, pure tone average; SSI-ICM, Synthetic Sentences Identification
 440 with Ipsilateral Competitive Message; MMSE, Mini Mental State Examination; HDL, high-density lipoprotein; LDL, low-density
 441 lipoprotein; SBP, systolic blood pressure
 442 ^ indicates p value < 0.05 for the comparison between groups using Pearson's chi-squared for categorical variables and Kruskal-
 443 Wallis one-way ANOVA followed by Nemenyi post-hoc test for quantitative parameters.
 444

445 **Table 2.** Prevalences of age-related central auditory processing disorder (CAPD) and cognitive
 446 status by gender.

	Males (<i>n</i> =951)	Females (<i>n</i> =907)	Total (<i>n</i> =1858)
Hearing Loss			
Age-related CAPD	120 (12.62)	90 (9.92)	210 (11.30)
SSI-ICM			
100-80%	352 (37.01)	389 (42.89)	741 (39.88)
70-50%	222 (23.34)	212 (23.37)	434 (23.36)
50-30%	58 (6.10)	42 (4.63)	100 (5.38)
20-0	181 (19.03)	147 (16.21)	328 (17.65)
Cognition			
Dementia	33 (3.47)	51 (5.62)	84 (4.52)
MCI	192 (20.19)	141 (15.54)	333 (17.92)

447 *All variables are categorics (%)

448 Abbreviations: ARHL, age-related hearing impairment; PTA, pure tone average; SSI-ICM, Synthetic Sentences
 449 Identification with Ipsilateral Competitive Message; MCI, mild cognitive impairment

450

451 **Table 3.** Prevalences of age-related central auditory processing disorder (CAPD) and cognitive
 452 status stratified by age classes.

	Age classes (yrs) (<i>n</i> =1931)				
	[65;70]	(70;75]	(75;80]	(80;85]	(85;90]
	(<i>n</i> =528)	(<i>n</i> =539)	(<i>n</i> =392)	(<i>n</i> =288)	(<i>n</i> =184)
Hearing Loss					
Age-related CAPD	32 (6.06)	59 (10.95)	53 (13.52)	41 (14.24)	29 (15.76)
Cognition					
Dementia	14 (2.65)	12 (2.23)	18 (4.59)	21 (7.29)	2 (1.09)
MCI	78 (14.77)	82 (15.21)	110 (28.06)	44 (15.28)	23 (12.50)

453 * All variables are categories (%)
 454
 455 Abbreviations: ARHL, age-related hearing impairment; MCI, mild cognitive impairment
 456

457 **Table 4.** Logistic regression of mild cognitive impairment (MCI) and dementia on single
 458 hearing status variables.

Parameters *	MCI				Dementia			
	OR	se(OR)	p-value	95% CI	OR	se(OR)	p-value	95% CI
Age-related CAPD	1.68	0.30	0.004	1.18 to 2.40	4.84	1.33	<0.001	2.82 to 8.31
Age-related CAPD [^]	1.50	0.30	0.04	1.01 to 2.21	2.23	0.78	0.02	1.12 to 4.42

459 *All variables included in the model were considered as categorical

460 [^] Adjusted for age, gender, years of education, blood glucose, total cholesterol and systolic blood pressure

461 Abbreviations: CAPD, central auditory processing disorder; OR, odds ratio; se, standard error; CI, confidence
 462 interval

463

464 **Table 5.** Linear regression of global cognitive functions (Mini Mental State Examination) on
 465 Synthetic Sentences Identification with Ipsilateral Competitive Message (SSI-ICM).

Parameter*	β	se(β)	p-value	95% CI
SSI-ICM	0.04	0.003	<0.001	0.03 to 0.04
SSI-ICM [^]	0.02	0.003	<0.001	0.01 to 0.03
SSI-ICM [°]	0.02	0.01	0.006	0.005 to 0.03

466 *All variables included in the model were considered as categorical, except the outcome

467 [^] Adjusted for age, gender, years of education, Glucose, total cholesterol, systolic blood pressure

468 [°] Adjusted for age, gender, years of education, glucose, total cholesterol, Smoking, systolic blood pressure and
 469 interaction between SSI-ICM and PTA (as continuous variable)

470 Abbreviations: β , coefficient; se, standard error; CI, confidence interval

471

472

473

474 **Legends to the Figures**

475

476 **Figure 1.** Prevalences of age-related central auditory processing disorder (CAPD) (Panel A),
477 mild cognitive impairment (MCI) (Panel B), and dementia (Panel C) stratified by age groups
478 ($n=1647$).